CTKB

Cytek BiosciencesD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$9.00

+114.8% vs current

Most likely

Base case

60%

Probability

Target price

$5.73

+36.8% vs current

B-

Bear case

20%

Probability

Target price

$3.00

-28.4% vs current

AI sentiment snapshot

Latest data as of 2026-01-29

AI commentary

Consensus is muted-to-cautious with price targets clustering near $6.00, implying limited near-term upside. Market attention is event-driven—earnings and placement cadence will likely move sentiment. Investors are waiting for clearer adoption signals before upgrading conviction.

RankAlpha Sentiment AI - 2026-01-29

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-04-29eventAnalyst coverage updates / price-target revisionsHigh impact

Multiple outlets list recent analyst targets and a small analyst panel (consensus ~$6.00) — coverage changes after results or model updates can reprice shares [#SERP-1][#SERP-7]. Assumes updates occur after the earnings cycle.

2026-04-29catalystNext quarterly earnings release (Q4 2025)High impact

Quarterly results and guidance could move the stock; analysts show a tight target range ahead of updates [#SERP-1][#SERP-4]. Date is estimated pending company schedule; assumed post-quarter reporting cycle.

2027-01-29catalystCommercial adoption and instrument install-base rampHigh impact

Sustained commercial adoption of spectral flow cytometry and consumables could drive multi-year revenue growth; market commentary and analyst forecasts imply upside if adoption accelerates [#SERP-3][#SERP-5].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-01-29 • Updated nightlySource: Internal modelMethodology